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5.5–8.5 %) and radiological incidence of 35.3 % (95 % CI 
26.4–44.3 %).
Conclusion Isolated foot and ankle surgery has a lower 
incidence of clinically apparent VTE when compared to 
general lower limb procedures, and this rate is not signifi-
cantly reduced using low molecular weight heparin. The 
incidence of VTE following Achilles tendon rupture is 
high whether treated surgically or conservatively. With the 
exception of those with Achilles tendon rupture, routine 
use of chemical VTE prophylaxis is not justified in those 
undergoing isolated foot and ankle surgery, but patient-spe-
cific risk factors for VTE should be used to assess patients 
individually.
Level of evidence II.
Keywords Deep vein thrombosis · Foot and ankle 
surgery · Venous thromboembolism · Low molecular 
weight heparin · Achilles tendon · Lower limb surgery
Introduction
25,000 people die each year in England from venous 
thromboembolism (VTE), more than the combined total 
of deaths from breast cancer, AIDS and road traffic acci-
dents [28]. The total cost (direct and indirect) to the UK for 
managing VTE is estimated at £640 million [28]. VTE has 
been highlighted as a particular risk following orthopaedic 
surgery or injury to the lower limb. However, most stud-
ies investigating VTE are conducted in patients undergoing 
major orthopaedic surgery at or above the knee [4, 5, 12, 
13, 17, 42, 49, 68, 72]. The risk of VTE for patients with 
isolated foot and ankle conditions, even with plaster cast 
immobilization, and the possible benefits of mechanical 
and chemical prophylaxis are poorly studied.
Abstract 
Purpose  To perform a meta-analysis investigating venous 
thromboembolism (VTE) following isolated foot and ankle 
surgery and propose guidelines for VTE prevention in this 
group of patients.
Methods Following a PRISMA compliant search, 372 
papers were identified and meta-analysis performed on 22 
papers using the Critical Appraisal Skills Programme and 
Centre for Evidence-Based Medicine level of evidence.
Results  43,381 patients were clinically assessed for VTE 
and the incidence with and without chemoprophylaxis was 
0.6 % (95 % CI 0.4–0.8 %) and 1 % (95 % CI 0.2–1.7 %), 
respectively. 1666 Patients were assessed radiologically 
and the incidence of VTE with and without chemoprophy-
laxis was 12.5 % (95 % CI 6.8–18.2 %) and 10.5 % (95 % 
CI 5.0–15.9 %), respectively. There was no significant dif-
ference in the rates of VTE with or without chemoprophy-
laxis whether assessed clinically or by radiological criteria. 
The risk of VTE in those patients with Achilles tendon rup-
ture was greater with a clinical incidence of 7 % (95 % CI 
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The NICE committee commissioned with assessment of 
VTE prevention concluded that for patients immobilized in 
a cast “This is a large patient group for whom the evidence 
is not clear” and went on to state “There would be a sub-
stantial cost to the NHS of providing thromboprophylaxis 
to all patients with a lower limb plaster cast, particularly if 
patients use prophylaxis until cast removal which may be 
a number of weeks” [53]. The American College of Chest 
Physicians (ACCP) most recent review also recommends 
against chemical prophylaxis in lower leg injuries requiring 
immobilization [15]. Despite this conclusion, many hospi-
tals are introducing policies which recommend the routine 
use of low molecular weight heparin (LMWH) chemopro-
phylaxis for those in a cast following ankle fractures and all 
forms of elective foot and ankle surgery.
In order to make such recommendations, the following 
criteria must be fulfilled:
1. There is a significant risk of VTE in those with isolated 
foot and ankle conditions.
2. The incidence of VTE is significantly reduced by pre-
scribing LMWH prophylaxis.
3. The risk of complications from LMWH outweighs the 
reduction in risk of VTE.
4. There is an appropriate cost–benefit using LMWH for 
VTE prophylaxis.
The purpose of this meta-analysis and review of the lit-
erature is to establish the incidence of VTE in orthopaedic 
foot and ankle patients, specifically investigating the effec-
tiveness and risk of chemoprophylaxis comparing clinical 
to radiographic outcome measures.
The aim of the paper is to identify those factors that 
increase the risk of VTE in patients with foot and ankle 
conditions and establish whether current guidelines should 
be revised to consider preventive methods in all or specific 
patients undergoing foot and ankle surgery.
Materials and methods
Search strategy
A PRISMA compliant search of AMED, EMBASE, HMIC, 
MEDLINE, BNI and CINAHL databases on the 31 January 
2015 was undertaken [51]. The search terms were: throm-
boembolism and (foot OR ankle) = 308 then combined 
with a search for: VTE and (foot OR ankle) = 64. Review 
of meeting abstracts and relevant references identified 
an additional 32 studies for potential inclusion. Fifty-two 
duplicates were removed and 328 articles excluded by title 
and abstract screening.
The methodological quality of each article was 
assessed using the Critical Appraisal Skills Programme 
(CASP) [59]. The CASP checklist assessed whether 
the aim of the paper was clear, the methods were valid 
(including study design, recruitment, bias and ethics) and 
there were a rigorous analysis of data and a clear state-
ment of findings. In total 28 articles were independently 
reviewed by two of the authors (RF and EDA) using 
the CASP tool and Centre for Evidence-Based Medi-
cine (CEBM) level of evidence [55]. Any discrepancies 
were resolved by consensus with the senior author (JC). 
Twenty-two studies met full inclusion criteria for the final 
analysis (Fig. 1).
Exclusions
Case reports
Non-original data, meta-analyses, etc.
Evidence level 4 and below
CASP score of 8 or less
Patients with pathology proximal to the mid-tibia
Studies with <12 patients per subgroup
Assumptions and simplifications
For the purposes of the meta-analysis, all studies were 
considered as cohorts, such that an RCT with two arms 
was considered as two separate cohorts. Patient cohorts 
have been simplified into two categories: general foot 
and ankle patients including elective and trauma patients 
that may or may not have required a below knee cast and 
patients with acute Achilles tendon rupture treated with 
or without surgery. Achilles patients were considered 
in a separate meta-analysis as they have been found to 
have significantly higher risks of VTE in some studies, 
and these studies were clearly outliers in our provisional 
review of the data.
LMWH regimens were considered to be equal although 
formulations and length of treatment may vary. Two further 
studies, one using extended intermittent pneumatic com-
pression devices (IPCDs) and one using aspirin, were also 
included in the prophylaxis group.
The principal study measures are VTE rates, a sum of 
the DVT and PE incidence.
Statistical advice was sought from the Biostatistics Unit, 
University College London, UK. Analysis was performed 
using STATA. The results are presented as incidence with 
95 % confidence intervals. A meta-analysis was performed 
initially using a fixed effects model with a test for homoge-
neity. If homogeneity was unlikely (a pre-hoc probability 
of p = 0.2), then a random effects model was used.
Knee Surg Sports Traumatol Arthrosc 
1 3
Results
Narrative results
In total 22 studies met the criteria for inclusion: 10 of these 
assessed VTE clinically, 7 with ultrasound and 5 with 
venography.
Patient populations
There was heterogeneity in the study populations with 
some studies offering data on various subgroups. Six stud-
ies considered general foot and ankle cases [16, 22, 24, 32, 
36, 40]. Twelve studies had trauma cohorts [21, 33, 36–38, 
41, 56, 57, 62, 66, 67, 69]. Six studies looked at Achilles 
injury, some of these included patients regardless of treat-
ment whilst others focused specifically on Achilles surgery 
[9, 26, 30, 36, 54, 64].
Prophylaxis
There was also some heterogeneity in prophylaxis regi-
mens. Most studies used LMWH either in comparison to no 
prophylaxis [21, 32, 33, 36–38, 42] or in isolation [24, 57, 
76]. One study compared aspirin with no prophylaxis [22] 
and another compared an Intermittent Pneumatic Compres-
sion Device with no prophylaxis [9]. The remaining studies 
used no formal post-operative prophylaxis [16, 26, 41, 54, 
62, 64, 66, 67] or were unclear [30, 69].
Methodological quality
The studies showed moderate-to-good methodologies 
according to the CASP appraisal tool. All studies were 
focused with an appropriate method and acceptable recruit-
ment. The exposure was generally measured to minimize 
bias (21/22) although there was a risk of bias in the out-
come measures of some (4/22). Confounding factors were 
identified in 14 of 22 studies and accounted for in the 
analysis of 15 of 23. Follow-up was considered complete 
enough in all but three of the studies (19/22), seven studies 
used large hospital databases to follow patients and 12 had 
over 80 % follow-up. The length of follow-up was 35 days 
or more in 11 studies, in a further seven studies using large 
hospital databases, it was assumed to be sufficient and in 
four was considered to be insufficient. All study popula-
tions were relevant, and the results were comparable to 
other studies in most cases (18/22). Overall, the authors 
were in favour of prophylaxis in seven studies, against in 
nine, and no clear conclusion was drawn in seven.
Fig. 1  Preferred reporting 
items for systematic reviews 
and meta-analyses (PRISMA) 
flow diagram of article selection
372 records identified through
database searching
32 additional records identified
through other sources
352 records screened after duplicates
removed
324 excluded based on
abstract/title, or data
from authors
28 full-text articles assessed for eligibility 6 full-text articles
excluded, with reasons
22 studies included in qualitative synthesis
404 total records identified
52 duplicate records
excluded
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Risk factors for VTE
Of the 12 studies that analysed risk factors for VTE, age 
was found to be a factor in six studies [32, 36, 37, 62, 
66, 67]; no statistical association with any risk factor was 
shown in three studies [21, 56, 57]; injury severity was 
associated with risk of VTE in two studies [62, 66]; obesity 
was a factor in three studies [16, 37, 66] and immobiliza-
tion was a factor in three studies [36, 62, 67]. Other risk 
factors found in individual studies were as following: non-
weight bearing [62], hindfoot surgery [67], tourniquet time 
[67], varicose vein [37] Charlson score >2 [32], NIDDM 
[32], air travel [24], prior VTE [16], hormone replacement 
therapy (HRT) and oral contraceptives [16].
Meta‑analysis results
To reduce the risk of heterogeneity in the study design 
affecting the results, the following meta-analyses were 
performed:
•	 All studies using clinical indicators as the primary 
assessment of VTE—this group was divided into patients 
who either received or did not receive prophylaxis.
•	 All studies using radiological means as the primary assess-
ment of VTE—again this group was divided into patients 
who either received or did not receive prophylaxis.
•	 Studies investigating VTE purely following Achilles 
tendon rupture were assessed separately as the high 
rates of DVT were obvious outliers when compared to 
other foot and ankle injuries or treatments [9, 26, 30, 40, 
54, 64].
•	 Studies where the prophylaxis regimen was unclear 
were excluded [30, 69].
Clinical assessment of VTE in patients with foot 
and ankle conditions
A total of 43,381 patients were clinically assessed for the 
presence of VTE. 126 of 27,139 patients without any form 
of prophylaxis developed VTE (0.46 %). The pooled effect 
size shows the incidence of VTE without prophylaxis to be 
0.6 % (95 % CI 0.4–0.8 %) (Fig. 2).
45 of 16,242 patients with prophylaxis developed 
VTE (0.28 %). The pooled effect size shows the inci-
dence of VTE with prophylaxis to be 1 % (95 % CI 
0.2–1.7 %) (Fig. 3). There was no significant difference 
in the rate of VTE between the groups with and without 
chemoprophylaxis.
Radiological assessment of VTE in patients with foot 
and ankle conditions
1666 Patients were assessed for radiological evidence of 
DVT. 120 of 981 patients without any form of prophylaxis 
developed VTE (12.2 %). The pooled effect size shows the 
incidence of VTE without prophylaxis to be 12.5 % (95 % 
CI 6.8–18.2 %) (Fig. 4).
54 of 685 patients with prophylaxis developed VTE 
(7.9 %). The pooled effect size shows the incidence 
of VTE with prophylaxis to be 10.5 % (95 % CI 5.0–
15.9 %) (Fig. 5). There was no significant difference in 
the rate of VTE between the groups with and without 
chemoprophylaxis.
Patients with Achilles tendon rupture
1060 patients were assessed clinically for evidence of DVT, 
and 74 were confirmed to have VTE (7 %). The pooled 
Fig. 2  Forest plot of clinical 
assessment of VTE without 
prophylaxis
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Fig. 3  Forest plot of clini-
cal assessment of VTE with 
prophylaxis
Fig. 4  Forest plot of radiologi-
cal assessment of VTE without 
prophylaxis
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Fig. 5  Forest plot of radio-
logical assessment of VTE with 
prophylaxis
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effect size shows the incidence of VTE to be 7 % (95 % CI 
5.5–8.5 %) (Fig. 6).
Hundred and seven patients were assessed for radiologi-
cal evidence of DVT and 38 were confirmed to have VTE 
(35.5 %). The pooled effect size shows the incidence of 
VTE to be 35.3 % (95 % CI 26.4–44.3 %) (Fig. 7).
Only one RCT reported the effect of LMWH on rate of 
VTE following immobilization of 105 patients with Achil-
les tendon rupture. There was no significant reduction in 
the rate of DVT with 34 % in the LMWH group and 36 % 
in the control group [42].
Discussion
The most important finding of this study is that there is a 
low risk of developing VTE following isolated foot and 
ankle surgery and no benefit could be demonstrated by 
using chemoprophylaxis. The incidence of VTE without 
prophylaxis was 0.6 % when diagnosed clinically and 
12.2 % with radiological diagnosis which is similar to the 
meta-analyses by Ettema et al. and Testroote et al. who 
both also reported on VTE following lower limb immobili-
zation [14, 70, 71]. It is also similar to the background risk 
of spontaneous VTE of 0.2–0.5 % [18, 25]. This is lower 
than in general orthopaedic surgery where the rate of DVT 
is reported as 40–60 % [23], but similar to the incidence of 
DVT following knee arthroscopy which has been reported 
as 0.6 % when diagnosed clinically and up to 17.9 % when 
using radiography [31, 60]. The consequences of asympto-
matic below knee DVT and the importance of its preven-
tion and treatment remains controversial and a systematic 
review of the treatment of below knee DVT’s concluded 
there was insufficient evidence to recommend treatment 
over mere surveillance [8, 19, 29, 34, 43, 45, 58, 61, 74].
Various methods of prophylaxis may be employed but 
no method completely protects against VTE [35]. LMWH 
is the current standard by which other chemical agents are 
Fig. 6  Forest plot of incidence 
of clinically assessed DVT in 
Achilles tendon rupture
Fig. 7  Forest plot of incidence 
of radiologically assessed DVT 
in Achilles tendon rupture
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Table 1  Characteristics of included studies
Author (year) [reference] Study design Number of 
patients
Patients Detection method CASP score 
(mean)
Domeij (2013) [10] RCT 24 DVT 2 and 6 weeks follow-
ing surgery for Achilles 
rupture—IPCD versus no 
prophylaxis
DVT—US 9
Felcher (2009) [16] Retrospective cohort 7264 Database search for VTE 
within 6 months of surgery
DVT—USS
PE—VQ/CTPA scan
10
Goel (2009) [21] RCT 238 LMWH versus placebo fol-
lowing surgery for below 
knee fractures
DVT—venography 10
Griffiths (2012) [22] Case control 2654 75 mg aspirin versus no 
chemical prophylaxis
Symptomatic VTE 9.5
Hanslow (2006) [24] Retrospective cohort 608 Foot and ankle surgery 
(high-risk patients received 
LMWH)
Symptomatic VTE 8.5
Healy (2010) [26] Retrospective cohort 208 Achilles rupture (cast and sur-
gery) no chemoprophylaxis
Symptomatic VTE con-
firmed by USS/CTPA
10
Ingvar (2005) [30] Retrospective cohort 196 Achilles rupture treated con-
servatively
Symptomatic VTE 8
Jameson (2014) [32] Retrospective cohort 88,241 Database search for VTE 
before and after introduc-
tion of NICE guidelines
Hospital episode statistics 10.5
Jorgensen (2002) [33] RCT 300 Below knee cast immobiliza-
tion—LMWH versus no 
prophylaxis
DVT—venography 9
Kock (1995) [36] RCT 339 Below knee cast immobiliza-
tion—LMWH versus no 
prophylaxis
DVT—USS confirmed with 
venography
10.5
Kujath (1993) [37] RCT 253 Below knee cast immobiliza-
tion—LMWH versus no 
prophylaxis
DVT—USS
PE—VQ
12
Lapidus (2013) [40] Prospective cohort 5894 No routine prophylaxis for 
foot and ankle surgery 
except LMWH for ankle 
fractures
DVT—USS
PE—VQ/CTPA scan
11
Lapidus (2007) [38] RCT 272 Ankle fractures—LMWH 
until cast removal versus no 
prophylaxis
DVT—venography 10.5
Lassen (2002) [41] RCT 440 Ankle fractures—LMWH 
until cast removal versus no 
prophylaxis
DVT—USS
PE—VQ/CTPA scan
10.5
Nilsson-Helander (2009) [54] RCT 95 Surgery versus no surgery 
for Achilles rupture—no 
routine prophylaxis
DVT—USS
PE—VQ/CTPA scan
9
Patil (2007) [56] Prospective cohort 100 Below knee cast immobiliza-
tion for ankle fractures—no 
routine prophylaxis
DVT—USS 10.5
Pelet (2012) [57] Retrospective cohort 1540 Surgery for ankle fracture—
no routine prophylaxis 
(141 low dose aspirin; 253 
LMWH)
Symptomatic VTE con-
firmed by USS/VQ/CTPA 
scan
11
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compared. However, the ideal duration of treatment has yet 
to be confirmed in orthopaedic surgery with some proto-
cols advocating treatment only whilst in hospital and others 
whilst immobilized or for an arbitrary period ranging from 
2 weeks to 35 days.
Out of hospital, compliance rates may drop below 85 % 
and oral agents may increase patient compliance [15, 47, 
73]. The ACCP review concluded that a 160 mg dose of 
aspirin for 35 days following lower limb injuries would 
prevent 7 per 1000 VTE’s but at the expense of three major 
bleeding episodes and two non-fatal myocardial infarctions 
[15]. Only one paper investigated the use of aspirin in foot 
and ankle surgery, and no benefit in protecting patients 
from VTE could be demonstrated [22]. To our knowledge, 
warfarin has not been investigated with regards to VTE 
prophylaxis in foot and ankle surgery. New oral anticoagu-
lants such as dabigatran and rivaroxaban are only currently 
licensed for use following elective hip and knee arthro-
plasty, and to date no studies have investigated their use in 
patients undergoing foot and ankle surgery [48].
Therefore, if chemoprophylaxis is to be recommended 
it would appear that only LMWH has a body of evidence 
to support its use. However, this meta-analysis has failed 
to demonstrate any significant reduction in the risk of VTE 
with the use of LMWH in foot and ankle conditions irre-
spective of the method of assessment—clinical assessment 
0.6 versus 1 % with prophylaxis (p = n.s.) and radiological 
assessment 12.5 versus 10.5 % with prophylaxis (p = n.s.).
In addition to the lack of effectiveness of chemoprophy-
laxis following isolated foot and ankle surgery, it is rec-
ognized there are potential risks of administering LWMH. 
These risks include bleeding (0.3–1 % following lower 
limb surgery) [17, 42, 46, 52], bruising and haematomas 
(12 %) [33, 42], wound healing problems and increased 
rate of wound infection, of particular concern in the foot 
and ankle [33, 36, 42]. Heparin-induced thrombocytopenia 
(HIT) is a potentially life-threatening adverse effect, more 
common in post-operative patients than medical patients 
with a rate of 2.6–6.5 % using unfractionated heparin and 
0.2–0.35 % with LMWH [6, 20, 44].
The risk of developing VTE in the subgroup of patients 
with Achilles tendon rupture appears to be particularly 
high whether treated surgically or non-operatively. Nils-
son-Helander et al. and Lapidus et al. both reported an 
incidence of 36 % when screened with USS [39, 54]. We 
separated Achilles tendon rupture patients from the main 
analysis as the results were clear outliers when compared 
with other foot and ankle conditions with few good-qual-
ity studies and only a small number of patients. It may be 
that because of direct involvement and de-functioning of 
the gastro-soleus complex, Achilles tendon ruptures need 
to be considered separately from general foot and ankle 
cases with regards to VTE prophylaxis. Although LMWH 
has been shown to have little or no effect in prevention of 
DVT following Achilles rupture [39], a recent RCT of 150 
patients using mechanical IPCDs for 2 weeks following 
Achilles tendon repair has demonstrated an absolute risk 
reduction for DVT of 37–21 % in the treated group (OR 
2.60; 95 % CI 1.15–5.91; p = 0.022) [10]. Active mechani-
cal methods address the problems of stasis, and further 
research into this area is justified.
This meta-analysis could be criticized for including 
studies with a wide variety of foot and ankle cases includ-
ing both elective and trauma. This trade-off increases the 
numbers included in the analysis at the expense of some 
clinical heterogeneity. However, we believe it represents 
the realities of clinical practice. The studies were also 
statistically heterogeneous which reflects differences in 
RCT randomized controlled trial, IPCD intermittent pneumatic compression device, VQ/CTPA scan ventilation-perfusion/computerized tomo-
graphic pulmonary angiography scan
Table 1  continued
Author (year) [reference] Study design Number of 
patients
Patients Detection method CASP score 
(mean)
Riou (2007) [62] Prospective cohort 2757 Below knee cast immobiliza-
tion—chemoprophylaxis 
versus no prophylaxis
DVT—USS 10.5
Shibuya (2012) [66] Retrospective cohort 75,664 Database search for foot and 
ankle trauma
Symptomatic VTE 10.5
Saragas (2011) [64] Retrospective cohort 88 Surgical repair Achilles rup-
ture—no prophylaxis
Symptomatic VTE con-
firmed by USS
8.5
Solis (2002) [67] Prospective cohort 201 No routine prophylaxis for 
foot and ankle surgery
DVT—USS 9
Soohoo (2011) [69] Retrospective cohort 57,183 Database search for ankle 
fractures undergoing 
surgery
Readmission for VTE 9
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study protocols, and we recognize that this heterogeneity 
limits the interpretation of any study on VTE rates in this 
population.
With the exception of age, the studies included in this 
review show conflicting results regarding risk factors such 
as restricted weight bearing, obesity and smoking where 
some studies report an association with VTE [3, 11, 50]. 
However, there was too much study heterogeneity to specif-
ically investigate the effect of individual risk factors. A his-
tory of previous VTE and thrombophilia has been shown to 
significantly increase the risk of further VTE with a 23 % 
5-year rate of recurrence of proximal DVT, 6 % for calf 
DVT and pulmonary embolus 3–4 times as likely to recur 
in a meta-analysis by Baglin et al. [1, 2].
Previous studies of chemical prophylaxis and RCTs of 
LMWH for lower limb immobilization have reported insig-
nificant effects in the prevention of DVT [14, 22, 38, 65]. A 
retrospective study of 664 total ankle replacements reported 
a clinical VTE rate of 0.6 % without prophylaxis, unless 
there was a previous history of VTE and a recent double-
blind RCT of the effects of LMWH following surgery and 
immobilization for lower leg fractures was stopped after 
interim analysis of 258 patients demonstrated an incidence 
of clinical VTE of 1.9 % and no significant benefit of using 
chemical prophylaxis [27, 65].
This paper would support the view that the risk–benefit 
of chemoprophylaxis for those with isolated foot and ankle 
conditions should be assessed separately from those under-
going general lower limb orthopaedic surgery. Although 
there was inconsistency in their effect on VTE risk in foot 
and ankle surgery, undoubtedly certain patient-related fac-
tors increase the risk of VTE including smoking, obesity, 
age >60 years, malignancy, HRT, oral contraception, pre-
vious VTE and thrombophilia and these should continue 
to be taken into account when assessment is made as to 
the need for chemoprophylaxis. It is also recognized that 
multiple risk factors are cumulative and two or more risk 
factors may lower the threshold for considering the benefit 
of chemoprophylaxis over the risks and costs of its use [7, 
63]. Mechanical methods such as TEDS and IPCDs may 
be a targeted alternative to chemoprophylaxis for DVT 
prevention in lower limb-immobilised patients after foot 
and ankle surgery. These patients should also routinely 
be encouraged to mobilize early and avoid dehydration 
(Table 1).
The findings of this meta-analysis are summarized using 
a Grade of Recommendation (Tables 2, 3), and guidelines 
for considering VTE prophylaxis in isolated foot and ankle 
conditions is proposed in Table 4 [75].
Table 2  Grades of recommendation for orthopaedic surgical studies
Grade of recommendation Description
A Good evidence (Level I studies with 
consistent findings) for or against 
recommending intervention
B Fair evidence (Level II or III studies 
with consistent findings) for or against 
recommending intervention
C Poor quality evidence (Level IV or V 
studies with consistent findings) for or 
against recommending intervention
I There is insufficient or conflicting evi-
dence not allowing a recommendation 
for or against intervention
Table 3  Grade of recommendation assigned summarizing main find-
ings of the meta-analysis
Routine chemoprophylaxis is not indicated for patients undergoing 
isolated foot and ankle surgery (Grade A recommendation)
Routine chemoprophylaxis is not indicated for patients with restricted 
weight bearing or immobilized for isolated foot and ankle condi-
tions (Grade B recommendation)
Routine use of mechanical anti-VTE methods is indicated following 
Achilles tendon rupture whether treated surgically or non-opera-
tively as there is a higher risk of VTE (Grade B recommendation)
Chemoprophylaxis with LMWH should be considered if two or more 
risk factors (smoking, obesity, age >60 years, malignancy, HRT, 
oral contraception, previous VTE and thrombophilia) are present in 
patients with isolated foot and ankle conditions (Grade C recom-
mendation)
Table 4  Suggested guidelines for prevention of VTE in routine 
isolated foot and ankle surgery (with/without immobilization and 
reduced weight bearing)
Start mechanical VTE prophylaxis at admission using one of the 
following:
 Anti-embolic stockings (thigh or knee length)—assuming no con-
traindications
 Foot impulse devices
 Intermittent pneumatic compression devices (thigh or knee length)
If patient has a history or previous VTE/thrombophilia or two or 
more risk factors below consider chemical prophylaxis (LMWH 
commencing 6–12 h after surgery until discharge from hospital or 
if immobilized and/or reduced weight bearing continue until the 
patient no longer has significantly reduced mobility)
 Active cancer or cancer treatment
 Age over 60 years
 Smoking
 Critical care admission
 Dehydration
 Obesity [body mass index (BMI) over 30 kg/m2]
 Use of hormone replacement therapy
 Use of oestrogen-containing contraceptive therapy
 Varicose veins with phlebitis
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Conclusion
The incidence of clinically apparent VTE following foot 
and ankle surgery is less than 1 % without using chemi-
cal prophylaxis, and no benefit could be demonstrated by 
using LMWH. Routine chemoprophylaxis cannot be rec-
ommended following isolated foot and ankle surgery. The 
one group where there may be a significant risk of VTE is 
following Achilles tendon rupture when specific preventa-
tive measures such as IPCDs may be indicated, and further 
research should investigate mechanical methods.
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